Altered expression patterns of syndecan-1 and-2 predict biochemical recurrence in prostate cancer
Author
dc.contributor.author
Ledezma, Rodrigo
Author
dc.contributor.author
Cifuentes, Federico
Author
dc.contributor.author
Gallegos, Iván
Author
dc.contributor.author
Fullá, Juan
Author
dc.contributor.author
Ossandon, Enrique
Author
dc.contributor.author
Castellon, Enrique A.
Author
dc.contributor.author
Contreras, Héctor R.
Admission date
dc.date.accessioned
2019-03-11T13:01:38Z
Available date
dc.date.available
2019-03-11T13:01:38Z
Publication date
dc.date.issued
2011
Cita de ítem
dc.identifier.citation
Asian Journal of Andrology, Volumen 13, Issue 3, 2018, Pages 476-480
Identifier
dc.identifier.issn
1008682X
Identifier
dc.identifier.issn
17457262
Identifier
dc.identifier.other
10.1038/aja.2010.143
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165223
Abstract
dc.description.abstract
The clinical features of prostate cancer do not provide an accurate determination of patients undergoing biochemical relapse and are therefore not suitable as indicators of prognosis for recurrence. New molecular markers are needed for proper pre-treatment risk stratification of patients. Our aim was to assess the value of altered expression of syndecan-1 and-2 as a marker for predicting biochemical relapse in patients with clinically localized prostate cancer treated by radical prostatectomy. The expression of syndecan-1 and-2 was examined by immunohistochemical staining in a series of 60 paraffin-embedded tissue samples from patients with localized prostate cancer. Ten specimens from patients with benign prostatic hyperplasia were used as non-malignant controls. Semiquantitative analysis was performed to evaluate the staining patterns. To investigate the prognostic value, Kaplan-Meier survival curves were performed and compared by a log-rank test. In benign samples, syndecan-1 was ex